Pen-G plant fire disruption
A fire incident at the Pen-G facility in Kakinada has halted production; resumption depends on regulatory approvals, impacting FY26 revenue and margin assumptions.
high · management_commentary
Aurobindo Pharma Limited — Q4 FY25
Aurobindo Pharma delivered a strong Q4 FY25 with revenue of INR 8,382 crore (+11% YoY) and EBITDA of INR 1,792 crore (21.4% margin), driven by volume growth in US and Europe, st...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Potential US tariffs on pharmaceutical imports
Tariff announcements expected in July 2025 could impact US business; management declined to provide specific guidance until clarity emerges.
medium · management_commentaryMuted injectable growth in FY26 due to Eugia-3 remediation
Eugia-3 facility remains under FDA remediation; injectable growth is expected to be flat in FY26, with recovery only in FY27.
medium · analyst_questionRevlimid revenue decline in FY26
Revenue from Revlimid will be significantly lower in FY26 as the product faces increased competition and limited remaining supply.
medium · analyst_question